Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype

International Journal of Hematology

Volumn 91, Issue 3, 2010, Pages 436-445

  Hemmati, Philipp G ^a   Terwey, Theis H ^a   Massenkeil, Gero ^b   Le Coutre, Philipp ^a   Vuong, Lam G ^a   Neuburger, Stefan ^a   Dörken, Bernd ^a   Arnold, Renate ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Stadtisches Krankenhaus Gutersloh   (Germany)

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; Reduced intensity conditioning

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENGRAFTMENT; FEMALE; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INTERMETHOD COMPARISON; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; AGED; CHROMOSOME ABERRATIONS; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 77950916947     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0515-y     Document Type: Article

References (54)

1. JJ Cornelissen WL van Putten LF Verdonck M Theobald E Jacky SM Daenen M van Marwijk Kooy P Wijermans H Schouten PC Huijgens, et al. 2007 Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 109 3658 3666 10.1182/blood-2006-06-025627 1:CAS:528:DC%2BD2sXkvFCitrs%3D 17213292 (Pubitemid 46641712)
2. PA Cassileth DP Harrington FR Appelbaum HM Lazarus JM Rowe E Paietta C Willman DD Hurd JM Bennett KG Blume, et al. 1998 Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission N Engl J Med 339 1649 1656 10.1056/NEJM199812033392301 1:STN:280:DyaK1M%2FktFWktw%3D%3D 9834301 (Pubitemid 28550689)
3. S Suciu F Mandelli T de Witte R Zittoun E Gallo B Labar G De Rosa A Belhabri R Giustolisi R Delarue, et al. 2003 Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial Blood 102 1232 1240 10.1182/blood-2002-12-3714 1:CAS:528:DC%2BD3sXmsFWksb8%3D 12714526 (Pubitemid 36988027)
4. S Tauro C Craddock K Peggs G Begum P Mahendra G Cook J Marsh D Milligan A Goldstone A Hunter, et al. 2005 Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia J Clin Oncol 23 9387 9393 10.1200/JCO.2005.02.0057 1:CAS:528:DC%2BD28Xnt1ymtg%3D%3D 16314618
5. D Valcarcel R Martino D Caballero J Martin C Ferra JB Nieto A Sampol MT Bernal JL Pinana L Vazquez, et al. 2008 Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival J Clin Oncol 26 577 584 10.1200/JCO.2007.11.1641 1:CAS:528:DC%2BD1cXis1als7k%3D 18086801 (Pubitemid 351264351)
6. TH Terwey G Massenkeil I Tamm PG Hemmati S Neuburger P Martus B Dorken D Hoelzer R Arnold 2008 Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy Bone Marrow Transplant 42 791 798 10.1038/bmt.2008.258 1:STN:280:DC%2BD1M%2FgtFSktg%3D%3D 18711350
7. ML Sorror MB Maris R Storb F Baron BM Sandmaier DG Maloney B Storer 2005 Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT Blood 106 2912 2919 10.1182/blood-2005-05-2004 1:CAS:528:DC%2BD2MXhtFantbfL 15994282 (Pubitemid 41510773)
8. ML Sorror S Giralt BM Sandmaier M De Lima M Shahjahan DG Maloney HJ Deeg FR Appelbaum B Storer R Storb 2007 Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences Blood 110 4606 4613 10.1182/blood-2007-06-096966 1:CAS:528:DC%2BD1cXot1en 17873123 (Pubitemid 351377830)
9. SW Kim K Matsuo T Fukuda M Hara K Matsue S Taniguchi T Eto M Tanimoto A Wake K Hatanaka, et al. 2008 Reduced-intensity unrelated donor bone marrow transplantation for hematologic malignancies Int J Hematol 88 324 330 10.1007/s12185-008-0163-7 18797985
10. O Ringden M Labopin G Ehninger D Niederwieser R Olsson N Basara J Finke R Schwerdtfeger M Eder D Bunjes, et al. 2009 Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia J Clin Oncol 27 4570 4577 10.1200/JCO.2008.20.9692 19652066
11. R Marks K Potthoff J Hahn G Ihorst H Bertz A Spyridonidis E Holler JM Finke 2008 Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies Blood 112 415 425 10.1182/blood-2007-08-104745 1:CAS:528:DC%2BD1cXos1Cit7c%3D 18451310
12. D Blaise N Vey C Faucher M Mohty 2007 Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia Haematologica 92 533 541 10.3324/haematol.10867 17488664 (Pubitemid 350147795)
13. G Massenkeil M Nagy P Le Coutre F Heine O Rosen B Dörken R Arnold 2004 Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD Hematol J 5 395 402 10.1038/sj.thj.6200543 15448665 (Pubitemid 39359275)
14. G Massenkeil M Nagy S Neuburger I Tamm C Lutz P le Coutre O Rosen KD Wernecke B Dörken R Arnold 2005 Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias Bone Marrow Transplant 36 683 689 10.1038/sj.bmt.1705123 1:STN:280:DC%2BD2MritleksA%3D%3D 16113673 (Pubitemid 41518710)
15. J Finke A Nagler 2007 Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning-is there still an upper age limit? A focus on myeloid neoplasia Leukemia 21 1357 1362 10.1038/sj.leu.2404741 1:CAS:528:DC%2BD2sXms1Wms7c%3D 17508002 (Pubitemid 46969869)
16. A Shimoni I Hardan N Shem-Tov M Yeshurun R Yerushalmi A Avigdor I Ben-Bassat A Nagler 2006 Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity Leukemia 20 322 328 10.1038/sj.leu.2404037 1:CAS:528:DC%2BD28Xmsl2qsg%3D%3D 16307018 (Pubitemid 43148672)
17. T Büchner WE Berdel C Schoch T Haferlach HL Serve J Kienast S Schnittger W Kern J Tchinda A Reichle, et al. 2006 Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia J Clin Oncol 24 2480 2489 10.1200/JCO.2005.04.5013 16735702 (Pubitemid 46655599)
18. ML Slovak KJ Kopecky PA Cassileth DH Harrington KS Theil A Mohamed E Paietta CL Willman DR Head JM Rowe, et al. 2000 Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study Blood 96 4075 4083 1:CAS:528:DC%2BD3cXosl2hsbo%3D 11110676
19. G Massenkeil M Nagy M Lawang O Rosen I Genvresse G Geserick B Dörken R Arnold 2003 Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved Bone Marrow Transplant 31 339 345 10.1038/sj.bmt.1703859 1:CAS:528:DC%2BD3sXhvFyns74%3D 12634724 (Pubitemid 36410679)
20. S Slavin A Nagler E Naparstek Y Kapelushnik M Aker G Cividalli G Varadi M Kirschbaum A Ackerstein S Samuel, et al. 1998 Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 91 756 763 1:STN:280: DyaK1c7hvVWrtQ%3D%3D 9446633 (Pubitemid 28078275)
21. G Socie 2004 Chronic graft-versus-host disease: clinical features and grading systems Int J Hematol 79 216 220 10.1532/IJH97.03174 15168587 (Pubitemid 38620768)
22. AH Filipovich D Weisdorf S Pavletic G Socie JR Wingard SJ Lee P Martin J Chien D Przepiorka D Couriel, et al. 2005 National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report Biol Blood Marrow Transplant 11 945 956 10.1016/j.bbmt.2005.09.004 16338616 (Pubitemid 41754712)
23. D Przepiorka D Weisdorf P Martin HG Klingemann P Beatty J Hows ED Thomas 1995 1994 Consensus Conference on Acute GVHD Grading Bone Marrow Transplant 15 825 828 1:STN:280:DyaK28%2Fot1Ojtw%3D%3D 7581076
24. S Giralt E Estey M Albitar K van Besien G Rondon P Anderlini S O'Brien I Khouri J Gajewski R Mehra, et al. 1997 Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 89 4531 4536 1:CAS:528:DyaK2sXjvFCkt7g%3D 9192777
25. K van Besien A Artz S Smith D Cao S Rich L Godley D Jones P Del Cerro D Bennett B Casey, et al. 2005 Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome J Clin Oncol 23 5728 5738 10.1200/JCO.2005.15.602 16009946 (Pubitemid 46300169)
26. A Shimoni N Kröger T Zabelina F Ayuk I Hardan M Yeshurun N Shem-Tov A Avigdor I Ben-Bassat AR Zander, et al. 2005 Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning Leukemia 19 7 12 10.1038/sj.leu.2403771 1:STN:280:DC%2BD2cnhvVKgtA%3D%3D 15526016 (Pubitemid 40861995)
27. M Mohty JO Bay C Faucher B Choufi K Bilger O Tournilhac N Vey AM Stoppa D Coso C Chabannon, et al. 2003 Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen Blood 102 470 476 10.1182/blood-2002-12- 3629 1:CAS:528:DC%2BD3sXlslGitro%3D 12649133 (Pubitemid 36841962)
28. U Hegenbart D Niederwieser BM Sandmaier MB Maris JA Shizuru H Greinix C Cordonnier B Rio A Gratwohl T Lange, et al. 2006 Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors J Clin Oncol 24 444 453 10.1200/JCO.2005.03.1765 1:CAS:528:DC%2BD28XhsFSku7k%3D 16344316 (Pubitemid 46630463)
29. E Estey M de Lima R Tibes S Pierce H Kantarjian R Champlin S Giralt 2007 Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) Blood 109 1395 1400 10.1182/blood-2006-05-021907 1:CAS:528:DC%2BD2sXjt1Cgsrk%3D 17038533 (Pubitemid 46239569)
30. R Martino D Valcarcel S Brunet A Sureda J Sierra 2008 Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission Bone Marrow Transplant 41 33 38 10.1038/sj.bmt.1705879 1:CAS:528: DC%2BD1cXmsV2hsA%3D%3D 17982504
31. DP Blaise J Michel Boiron C Faucher M Mohty JO Bay VJ Bardoux V Perreau D Coso A Pigneux N Vey 2005 Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment Cancer 104 1931 1938 10.1002/cncr.21418 1:CAS:528:DC%2BD2MXht1aqsrfE 16178004 (Pubitemid 41513177)
32. E Jourdan JM Boiron N Dastugue N Vey G Marit F Rigal-Huguet L Molina N Fegueux A Pigneux C Recher, et al. 2005 Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience J Clin Oncol 23 7676 7684 10.1200/JCO.2005.02.5940 16186596
33. LC Feinstein BM Sandmaier U Hegenbart PA McSweeney DG Maloney TA Gooley MB Maris TR Chauncey B Bruno FR Appelbaum, et al. 2003 Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission Br J Haematol 120 281 288 10.1046/j.1365-2141.2003.04057.x 12542488 (Pubitemid 36194179)
34. M Mohty H de Lavallade P Ladaique C Faucher N Vey D Coso AM Stoppa JA Gastaut D Blaise 2005 The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison Leukemia 19 916 920 10.1038/sj.leu.2403770 1:STN:280: DC%2BD2M3mvFGgtA%3D%3D 15843817 (Pubitemid 40862000)
35. M Mohty H de Lavallade J El-Cheikh P Ladaique C Faucher S Furst N Vey D Coso AM Stoppa JA Gastaut, et al. 2009 Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison Leukemia 23 194 196 10.1038/leu.2008.164 1:STN:280:DC%2BD1M%2Fmslekug%3D%3D 18580956
36. C Schmid M Schleuning G Ledderose J Tischer HJ Kolb 2005 Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome J Clin Oncol 23 5675 5687 10.1200/JCO.2005.07.061 16110027 (Pubitemid 46300164)
37. C Schmid M Schleuning R Schwerdtfeger B Hertenstein E Mischak-Weissinger D Bunjes SV Harsdorf C Scheid U Holtick H Greinix, et al. 2006 Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation Blood 108 1092 1099 10.1182/blood-2005-10-4165 1:CAS:528:DC%2BD28XnvFajurg%3D 16551971 (Pubitemid 44154650)
38. H Ogawa K Ikegame M Kawakami S Takahashi H Sakamaki T Karasuno H Sao Y Kodera N Hirabayashi S Okamoto, et al. 2004 Impact of cytogenetics on outcome of stem cell transplantation for acute myeloid leukemia in first remission: a large-scale retrospective analysis of data from the Japan Society for Hematopoietic Cell Transplantation Int J Hematol 79 495 500 10.1532/IJH97.03166 15239403 (Pubitemid 38808369)
39. M de Lima A Anagnostopoulos M Munsell M Shahjahan N Ueno C Ippoliti BS Andersson J Gajewski D Couriel J Cortes, et al. 2004 Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation Blood 104 865 872 10.1182/blood-2003-11-3750 15090449 (Pubitemid 38970586)
40. M Aoudjhane M Labopin NC Gorin A Shimoni T Ruutu HJ Kolb F Frassoni JM Boiron JL Yin J Finke, et al. 2005 Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT) Leukemia 19 2304 2312 10.1038/sj.leu.2403967 1:CAS:528:DC%2BD2MXht1ems7bN 16193083 (Pubitemid 41748028)
41. C Schmid M Labopin A Nagler M Bornhäuser J Finke A Fassas L Volin G Gurman J Maertens P Bordigoni, et al. 2007 Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party J Clin Oncol 25 4938 4945 10.1200/JCO.2007.11.6053 1:CAS:528:DC%2BD2sXhtlOhtbfI 17909197 (Pubitemid 350225492)
42. MS Tallman GW Dewald S Gandham BR Logan A Keating HM Lazarus MR Litzow J Mehta T Pedersen WS Perez, et al. 2007 Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission Blood 110 409 417 10.1182/blood-2006-10-043299 1:CAS:528:DC%2BD2sXnsVait7g%3D 17374741 (Pubitemid 47026863)
43. M Stelljes M Bornhäuser M Kröger J Beyer MC Sauerland A Heinecke B Berning C Scheffold G Silling T Büchner, et al. 2005 Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia Blood 106 3314 3321 10.1182/blood-2005-04-1377 1:CAS:528:DC%2BD2MXht1WntrvK 16020510 (Pubitemid 41565935)
44. C Schmid M Schleuning M Hentrich GE Markl A Gerbitz J Tischer G Ledderose D Oruzio W Hiddemann HJ Kolb 2008 High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission Bone Marrow Transplant 41 721 727 10.1038/sj.bmt.1705965 1:CAS:528: DC%2BD1cXkvFOlsbk%3D 18176613 (Pubitemid 351596039)
45. T Büchner WE Berdel B Wörmann C Schoch T Haferlach S Schnittger W Kern C Aul E Lengfelder A Schumacher, et al. 2005 Treatment of older patients with AML Crit Rev Oncol Hematol 56 247 259 10.1016/j.critrevonc.2004.09.010 16246568 (Pubitemid 41568580)
46. S Fröhling RF Schlenk S Kayser M Morhardt A Benner K Döhner H Döhner 2006 Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B Blood 108 3280 3288 10.1182/blood-2006-04-014324 16840728
47. PD Kottaridis DW Milligan R Chopra RK Chakraverty S Chakrabarti S Robinson K Peggs S Verfuerth R Pettengell JC Marsh, et al. 2000 In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation Blood 96 2419 2425 1:CAS:528:DC%2BD3cXntVarurc%3D 11001893
48. PA McSweeney D Niederwieser JA Shizuru BM Sandmaier AJ Molina DG Maloney TR Chauncey TA Gooley U Hegenbart RA Nash, et al. 2001 Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 3390 3400 10.1182/blood.V97.11.3390 1:CAS:528:DC%2BD3MXktFOkt7c%3D 11369628
49. KM Sullivan PL Weiden R Storb RP Witherspoon A Fefer L Fisher CD Buckner C Anasetti FR Appelbaum C Badger, et al. 1989 Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia Blood 73 1720 1728 1:STN:280:DyaL1M3ivFCjtQ%3D%3D 2653460 (Pubitemid 19133213)
50. ME Horwitz KM Sullivan 2006 Chronic graft-versus-host disease Blood Rev 20 15 27 10.1016/j.blre.2005.01.007 16426941 (Pubitemid 43106715)
51. N Kroger T Zabelina W Kruger H Renges N Stute J Rischewski S Sonnenberg F Ayuk F Togel U Schade, et al. 2002 In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors Bone Marrow Transplant 29 683 689 10.1038/sj.bmt.1703530 1:STN:280:DC%2BD38vitlSnsw%3D%3D 12180114 (Pubitemid 34591312)
52. M Mohty M Kuentz M Michallet JH Bourhis N Milpied L Sutton JP Jouet M Attal P Bordigoni JY Cahn, et al. 2002 Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study Blood 100 3128 3134 10.1182/blood.V100.9.3128 1:CAS:528: DC%2BD38XosVSisL4%3D 12384409 (Pubitemid 35217059)
53. J Sierra R Martino B Sanchez JL Pinana D Valcarcel S Brunet 2008 Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia Bone Marrow Transplant 41 425 437 10.1038/sj.bmt.1705973 1:STN:280:DC%2BD1c7nsVymsQ%3D%3D 18209727 (Pubitemid 351395096)
54. D Valcarcel R Martino A Sureda C Canals A Altes J Briones MA Sanz R Parody M Constans SL Villela, et al. 2005 Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies Eur J Haematol 74 144 151 10.1111/j.1600-0609.2004. 00360.x 1:STN:280:DC%2BD2M%2FivVCiuw%3D%3D 15654906 (Pubitemid 40175319)